Microsoft Corp. has spent more than $100 billion on its partnership with OpenAI, a sum that underscores the significance of the software maker’s role in the AI company’s growth. That figure includes Microsoft’s original investments in OpenAI, as well as the costs of building infrastructure and hosting OpenAI’s computing, Microsoft deals executive Michael Wetter testified on Monday. It is cumulativ...
Microsoft Corp. has spent more than $100 billion on its partnership with OpenAI, a sum that underscores the significance of the software maker’s role in the AI company’s growth. That figure includes Microsoft’s original investments in OpenAI, as well as the costs of building infrastructure and hosting OpenAI’s computing, Microsoft deals executive Michael Wetter testified on Monday. It is cumulative through the current fiscal year which ends in June, he said. Many of these costs were incurred before receiving any revenue, Wetter said. “We needed to build Azure infrastructure in advance of providing those services to OpenAI,” he said, referring to Microsoft’s cloud-computing division. Wetter was testifying as part of Elon Musk ’s high-profile case against OpenAI and Microsoft in federal court in Oakland, California. In a 2024 lawsuit, Musk accused fellow OpenAI co-founders Sam Altman and Greg Brockman of abandoning the startup’s founding mission as a nonprofit to benefit humanity when it took steps to operate as a for-profit business. The world’s richest person alleged that Microsoft aided that alleged betrayal. Read More: Musk Testifies He’s Suing OpenAI to Stop Altman’s ‘Looting’ Microsoft invested about $13 billion in the ChatGPT maker through early 2023 and has been its primary cloud infrastructure provider. Last week, Chief Executive Officer Satya Nadella said that the company targeted a $92 billion return from its large early investments in OpenAI. The investments “worked out well because we took the risk,” Nadella said during his testimony. Since then, OpenAI’s valuation has skyrocketed to $852 billion as of the end of March. As of October, Microsoft’s stake in the company was valued at about $135 billion. Microsoft and OpenAI have squabbled over the terms of their partnership and over time have come into more direct competition with one another. As part of OpenAI’s restructuring last year, Microsoft received a 27% ownership stake in the startup. OpenAI, Altman...
Shares of JD.Com Inc (NASDAQ:JD) surged on Wednesday after the company posted strong first-quarter (Q1) results. Benchmark analyst Fawne Jiang said the Q1 results and second-quarter outlook point to "a clear earnings inflection point," with profitability growth "firmly back on track." The JD.Com Analyst: Jiang, reiterated a Buy rating and raised the price target from $38 to $42. The JD.Com Thesis:...
Shares of JD.Com Inc (NASDAQ:JD) surged on Wednesday after the company posted strong first-quarter (Q1) results. Benchmark analyst Fawne Jiang said the Q1 results and second-quarter outlook point to "a clear earnings inflection point," with profitability growth "firmly back on track." The JD.Com Analyst: Jiang, reiterated a Buy rating and raised the price target from $38 to $42. The JD.Com Thesis: Despite a challenging backdrop, the company delivered modestly better-than-expected revenue, margin
Novo Nordisk (NYSE: NVO) has significantly lagged the broader market over the past two years, losing more than 60% of its market value. However, the drugmaker's shares have performed well over the past month. The company's recent first-quarter update, released on May 6, helped push the stock even higher. Can Novo Nordisk sustain this recent momentum? Novo Nordisk's first-quarter results don't look...
Novo Nordisk (NYSE: NVO) has significantly lagged the broader market over the past two years, losing more than 60% of its market value. However, the drugmaker's shares have performed well over the past month. The company's recent first-quarter update, released on May 6, helped push the stock even higher. Can Novo Nordisk sustain this recent momentum? Novo Nordisk's first-quarter results don't look great on the surface. The company's adjusted net sales decreased 10% year over year to 70.1 billion Danish kroner (about $11 billion). Adjusted earnings per share dropped 3% year over year to 6.63 DKK ($1.03). But here's the thing: Novo Nordisk had already projected that its revenue and earnings would decline this year. The surprise in the company's quarterly update was that, although poor financial results were already baked into the stock price, things weren't nearly as bad as the market expected. Novo Nordisk can thank oral Wegovy, which it launched in January, for that. Oral Wegovy has experienced strong adoption, with over two million patients already on the pill. Image source: The Motley Fool. Continue reading
An outbreak of the hantavirus on a cruise ship recently sparked a bit of a rally in the pharmaceutical and biotech industries. While no one hopes this will become a global health crisis, if it does, those companies that develop and market effective vaccines for the hantavirus may be financially rewarded, so the argument goes. However, at this stage, it is likely not a good idea to buy into this ra...
An outbreak of the hantavirus on a cruise ship recently sparked a bit of a rally in the pharmaceutical and biotech industries. While no one hopes this will become a global health crisis, if it does, those companies that develop and market effective vaccines for the hantavirus may be financially rewarded, so the argument goes. However, at this stage, it is likely not a good idea to buy into this rally. Let's consider three reasons why. Image source: Getty Images. While this is an evolving situation and we may not have all the facts yet, the information we have suggests that this is unlikely to become a global health crisis on the scale of the coronavirus pandemic. Here's why. COVID-19 spreads through respiratory droplets from an infected person. The hantavirus, by contrast, is primarily transmitted by contact with the saliva, droppings, or urine of infected rodents. Continue reading
Anduril is being valued at $61 billion in a $5 billion funding round led by Thrive Capital and Andreessen Horowitz to invest “aggressively” in manufacturing capacity, research and development and infrastructure. Anduril CEO Brian Schimpf joins Ed Ludlow and Caroline Hyde to discuss on "Bloomberg Tech." (Source: Bloomberg)
Anduril is being valued at $61 billion in a $5 billion funding round led by Thrive Capital and Andreessen Horowitz to invest “aggressively” in manufacturing capacity, research and development and infrastructure. Anduril CEO Brian Schimpf joins Ed Ludlow and Caroline Hyde to discuss on "Bloomberg Tech." (Source: Bloomberg)
Fervo Energy Co. shares opened 33% above their IPO price after the geothermal energy developer raised $1.89 billion in an upsized US initial public offering. Shares of the Houston-based firm opened at $36 each on Wednesday, versus an IPO price of $27. The listing priced above the marketed $25 to $26 range, which had been raised. The trading gives Fervo a market value of $10.2 billion based on the ...
Fervo Energy Co. shares opened 33% above their IPO price after the geothermal energy developer raised $1.89 billion in an upsized US initial public offering. Shares of the Houston-based firm opened at $36 each on Wednesday, versus an IPO price of $27. The listing priced above the marketed $25 to $26 range, which had been raised. The trading gives Fervo a market value of $10.2 billion based on the outstanding shares listed in its filings. The IPO drew orders for about 15 times the number of shares available, people familiar with the matter have said . Fervo uses horizontal drilling and multi-stage hydraulic fracturing to produce geothermal energy at its pilot project in Nevada, and it expects to deliver power at its first commercial station by the end of 2026. The company’s Cape Station project in Beaver County, Utah, would be one of the world’s largest geothermal projects with 500 megawatts of power capacity. With backing from Bill Gates ’ investment firm Breakthrough Energy Ventures and shale oil producer Devon Energy Corp. , Fervo is among a number of energy producers seeking to capitalize on the growing power demand for data centers. The company has about a $7.2 billion potential backlog of contracted revenue from power purchase agreements across its full portfolio, according to the filings. “There’s just a laser focus of investors right now on what are we going to do to solve the power demand imbalance we’re seeing in the country right now,” Fervo Chief Executive Officer Tim Latimer said in an interview. “There’s room for a lot of folks and I think that’s where you’re seeing investors place their bets.” Fervo also has power agreements with Southern California Edison Co. , Alphabet Inc. ’s Google and Shell Plc . Alphabet was part of a $462 million investment round in December. The geothermal company is pledging that its future projects could supply more power to the US’ growing fleet of data centers. That’s why geothermal is one of the only renewable energy secto...
(RTTNews) - European stocks closed higher on Wednesday, bouncing back fairly well from previous session's losses, as investors reacted to earnings and looked ahead to the U.S.-China summit in Beijing, in addition to following the developments on the Middle East conflict front.
(RTTNews) - European stocks closed higher on Wednesday, bouncing back fairly well from previous session's losses, as investors reacted to earnings and looked ahead to the U.S.-China summit in Beijing, in addition to following the developments on the Middle East conflict front.
Global events like the Iran conflict and the rise of artificial intelligence are creating increased demand for Honeywell International Inc. products ahead of its split later this month, according to the companies chief executive officer Vimal Kapur. He speaks with Dani Burger on "Bloomberg Deals." (Source: Bloomberg)
Global events like the Iran conflict and the rise of artificial intelligence are creating increased demand for Honeywell International Inc. products ahead of its split later this month, according to the companies chief executive officer Vimal Kapur. He speaks with Dani Burger on "Bloomberg Deals." (Source: Bloomberg)
Gens Aurea SpA is gearing up for an initial public offering that could raise between €300 million ($351.3 million) and €500 million, according to people familiar with the matter, in what could be Milan’s largest first-time share sale in three years. The cash-for-gold trader and its majority owner DVC Partners are considering launching an offering as soon as the coming months, the people said, who ...
Gens Aurea SpA is gearing up for an initial public offering that could raise between €300 million ($351.3 million) and €500 million, according to people familiar with the matter, in what could be Milan’s largest first-time share sale in three years. The cash-for-gold trader and its majority owner DVC Partners are considering launching an offering as soon as the coming months, the people said, who asked not be identified because the discussions are private. The offering may not raise any new funds for the company, with only shareholders selling shares, they said. Gens Aurea is working with bankers at BNP Paribas SA and Jefferies Financial Group Inc. to arrange the transaction, the people said. UniCredit SpA will also help arrange the deal, they said. No final decisions have been made, and the timing and structure of the deal remain subject to change, the people said. Representatives for DVC Partners, Jefferies and UniCredit declined to comment. Gens Aurea and BNP Paribas did not immediately respond to a request for comment. Osnago, Italy-based Gens Aurea buys and sells gold and jewelry through multiple brands across Europe including Orocash and Superefectivo. It manages more than 10 tons of gold per year and has annual sales of over €855 million, according to its website . DVC Partners acquired the company in 2019. Gens Aurea is one of a handful of companies considering going public before the investors break for the summer after the war in Iran prompted some issuers to shift their timetables to the autumn. Its IPO could be the largest to take place on the Milan bourse since Lottomatica Group SpA ’s in 2023, according to data compiled by Bloomberg.
Sempra ( SRE ) declares $0.6575/share quarterly dividend , in line with previous. Forward yield 2.84% Payable July 15; for shareholders of record June 25; ex-div June 25. See SRE Dividend Scorecard, Yield Chart, & Dividend Growth. More on Sempra Sempra: Oncor's 127 GW Pipeline Could Redefine Its Earnings Power Sempra 2026 Q1 - Results - Earnings Call Presentation Sempra (SRE) Q1 2026 Earnings Call...
Sempra ( SRE ) declares $0.6575/share quarterly dividend , in line with previous. Forward yield 2.84% Payable July 15; for shareholders of record June 25; ex-div June 25. See SRE Dividend Scorecard, Yield Chart, & Dividend Growth. More on Sempra Sempra: Oncor's 127 GW Pipeline Could Redefine Its Earnings Power Sempra 2026 Q1 - Results - Earnings Call Presentation Sempra (SRE) Q1 2026 Earnings Call Transcript Sempra affirms 2026 adjusted EPS $4.80-$5.30 while targeting SI Partners close in Q2-Q3 2026 Sempra misses top-line estimates; updates FY26 outlook
Taiwan Semiconductor Manufacturing Company Limited (TSM): Top AI Stock to Buy According to Billionaire David Tepper on Robust Revenue Growth Insider Monkey
Taiwan Semiconductor Manufacturing Company Limited (TSM): Top AI Stock to Buy According to Billionaire David Tepper on Robust Revenue Growth Insider Monkey
Yunfeng Financial is leveraging its strong balance sheet and a strategic ether reserve to turn physical assets into a digital financial tool for professional investors in Hong Kong image credit: Bamboo Works Key Takeaways: Yunfeng Financial has launched a digital token backed by gold bullion for professional investors in Hong Kong on its Yunfeng Youyu platform The company is leveraging capital res...
Yunfeng Financial is leveraging its strong balance sheet and a strategic ether reserve to turn physical assets into a digital financial tool for professional investors in Hong Kong image credit: Bamboo Works Key Takeaways: Yunfeng Financial has launched a digital token backed by gold bullion for professional investors in Hong Kong on its Yunfeng Youyu platform The company is leveraging capital reserves from its core insurance business to power a new model aimed at turning gold bullion into a liq
design master Replimune ( REPL ), which has been critical of the FDA over its application for a melanoma treatment, is up ~30% Wednesday, the day after FDA Commissioner Marty Makary tendered his resignation. Makary left his position Tuesday amid reported pressure from President Trump who noted that he had been having "some difficulty" heading the agency. Many in the pharmaceutical and biotech indu...
design master Replimune ( REPL ), which has been critical of the FDA over its application for a melanoma treatment, is up ~30% Wednesday, the day after FDA Commissioner Marty Makary tendered his resignation. Makary left his position Tuesday amid reported pressure from President Trump who noted that he had been having "some difficulty" heading the agency. Many in the pharmaceutical and biotech industries were also unhappy with his leadership. Replimune is the latest biopharma to have a spat with the agency. In April, the FDA rejected its melanoma therapy, RP1, plummeting shares , even though the company included input in its application from a Type A meeting. Makary responded to the attack with an op-ed defending the agency's decision in The Wall Street Journal . However, the newspaper's editorial board also published an editorial lamenting some of Makary's actions. In a just-published piece, Seeking Alpha investing group Galzus Research is maintaining a cautious buy rating and sees a potential for an RP1 resubmission with Makary gone. More on Replimune Group Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1 Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives Replimune: Multiple Shots On Goal But A High Risk Binary Approaches FDA head Makary defends drug application rejections amid criticism RFK Jr. says no hand in rejecting Replimune’s lead asset